Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: viral vaccines - Innogenetics

Drug Profile

Research programme: viral vaccines - Innogenetics

Alternative Names: ED 002; ED 009; EP 2220; EP 2230; GNI-103; GNI-105

Latest Information Update: 24 Mar 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genencor International; Pharmexa-Epimmune
  • Developer Innogenetics; Pharmexa-Epimmune
  • Class Papillomavirus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hepatitis C; Human papillomavirus infections

Most Recent Events

  • 28 May 2009 Pharmexa Epimmune has been acquired and merged into VaxOnco
  • 09 Sep 2008 Innogenetics has been acquired by Solvay Pharmaceuticals
  • 05 Sep 2007 Preclinical development of vaccine candidates ED 002 and ED 009 is ongoing
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top